Sort by
Keyphrases
Pediatric Patients
100%
Atypical Hemolytic Uremic Syndrome (aHUS)
100%
Pharmacological Management
100%
Eculizumab
36%
Monoclonal Antibody
9%
Kidney
9%
Effective Treatment
9%
Dose Rate
9%
Inconsistent Results
9%
Overactivation
9%
Quality of Life Improvement
9%
Thrombocytopenia
9%
Complement System
9%
Pretransplant
9%
Disease Risk
9%
Dialysis
9%
Recurrent Disease
9%
Blockage
9%
Acute Kidney Injury
9%
Regulatory Factors
9%
End-stage Kidney Disease
9%
Early Administration
9%
Kidney Transplantation
9%
Systemic Manifestations
9%
Meningococcal Infection
9%
Drug Discontinuation
9%
Close Monitoring
9%
Hematological Manifestations
9%
Thrombotic Microangiopathy
9%
Pathogenic Genetic Variants
9%
Component Factor
9%
Plasma Therapy
9%
C5 Antibody
9%
Restrictive Practices
9%
Ravulizumab
9%
Medicine and Dentistry
Pediatrics Patient
100%
Atypical Hemolytic Uremic Syndrome
100%
Eculizumab
36%
Recurrent Disease
18%
Quality of Life
9%
End Stage Renal Disease
9%
Monoclonal Antibody
9%
Thrombocytopenia
9%
Complement System
9%
Acute Kidney Injury
9%
Thrombotic Thrombocytopenic Purpura
9%
Kidney Transplantation
9%
Meningococcal Disease
9%
Ravulizumab
9%